Navigation Links
MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Date:8/19/2007

- Company Further Expands Anti-Interleukin-9 Program with Second Phase 2a

Study -

GAITHERSBURG, Md., Aug. 1 /PRNewswire/ -- MedImmune, Inc. today announced that it has initiated a multi-dose, Phase 2a clinical trial with its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma. The placebo-controlled, dose-escalation study is designed to evaluate the safety and tolerability of multiple doses of the antibody. This trial is the second Phase 2a study currently underway with the MAb, known as MEDI-528.

"We are excited to advance the investigation of this potential treatment for patients with asthma and to further explore the role of IL-9 in the pathology of this disease," said Barbara White, M.D., vice president, clinical development, inflammatory disease. "Recent preclinical study results have provided new insight about IL-9's role in a host of functions associated with the onset of asthma, including allergic inflammation in the airways and allergen-induced airway modeling. These data further support our hypothesis that an antibody blocking IL-9 may represent a new long-term maintenance or controller therapy for symptomatic, persistent asthma."

Two Phase 1 single-dose, dose-escalation studies have been conducted to evaluate the safety, tolerability and pharmacokinetics of the anti-IL-9 MAb in healthy volunteers. The antibody was well tolerated in both studies. The company is also conducting an ongoing Phase 2a study, initiated in late 2006, to evaluate the efficacy of a single intravenous dose of MEDI-528 and its effect on disease mechanisms in adults with atopic asthma. MedImmune plans to initiate a third Phase 2a study to evaluate the ability of MEDI-528 to inhibit the biological activity of IL-9 in the bronchoalveolar lavage fluid of adult patients with atopic asthma.

About IL-9

As mentioned above, IL-9 has been associated with symptoms of asthma. It is
'/>"/>

SOURCE MedImmune, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
11. Malvern initiates European user group meetings for chemical imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Research and Markets has ... Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market ... offering. On the basis of ... has been divided into eight major segments, namely, ... hydromechanical ablation technologies. The light/laser ablation technology segment ...
(Date:9/22/2014)... Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... fiscal 2014 ended July 31, 2014 on Monday, September 29 ... discuss the results at 11:00 AM ET. Participating in the ... Andrew A. Krakauer , President and CEO; Jorgen B. ... Sheldon , Senior Vice President, CFO and Treasurer; and ...
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4
... Ad, " This is Medicare and America at ... WASHINGTON, Dec. 9 The SCOOTER Store today launched a ... and cost savings associated with Medicare,s Power Mobility Benefit, which ... to receive power wheelchairs. , With budget cuts likely in ...
... , ROCKVILLE, Md., Dec. 9 Novavax, Inc. (Nasdaq: ... closed its previously announced public offering of 6,800,000 shares of ... net proceeds from the sale of the shares, after underwriting ... which will be used for preclinical studies and clinical trials ...
Cached Medicine Technology:The SCOOTER Store Launches New Advertising Highlighting the Value and Cost Savings From Medicare's Power Mobility Benefit 2NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2
(Date:9/22/2014)... people both exercise more and drink more , Study ... activity , Findings differ from past research on physical ... Medicine study finds that on days when people exercise ... more alcohol, too. , This is the only study ... for self-reporting physical activity and alcohol use. , "Monday ...
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... Boston Scientific Corp. continue to move forward in ... District Court, Southern District of West Virginia, Bernstein ... new Docket Control Order was issued by the ... of matters pertaining to the upcoming trial for ...
(Date:9/22/2014)... to 40 percent of patients undergoing breast cancer surgery ... all the cancerous tissue in the initial operation. However, ... tested a tool they developed that will help surgeons ... decreasing the chances for repeat operations. ... September 22, 2014 in the Proceedings of the ...
(Date:9/22/2014)... September 22, 2014 An inventor and ... to the problem of side-sleeping. "My lower arm always ... I designed a solution to this problem," she said. ... than to have your arm 'fall asleep.'" , The ... or her side more comfortably. It avoids pain and ...
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
Breaking Medicine News(10 mins):Health News:We drink more alcohol on gym days 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4Health News:The fine line between breast cancer and normal tissues 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4
... 7 NHS Choices ( http://www.nhs.uk ), the,online ... updated online information,resource, Health A-Z, aimed to help ... treatments., Based on NHS accredited information, the ... need,to know on a topic in seconds, providing ...
... conventional gasoline and stored electricity can be no ... technology is developed, according to researchers in France. ... Automotive Technology and Management, they suggest that the ... more sustainable fuel-cell powered electric vehicles. , Jean-Jacques ...
... Pa., Feb. 7 The following release was issued,today ... Milberg Weiss,LLP:, UNITED STATES DISTRICT COURT ... MARTEK BIOSCIENCES CORP. (Ticker: MATK) SECURITIES LITIGATION Civil ... SETTLEMENT AND SETTLEMENT HEARING TO: ALL PERSONS AND ...
... Learning, NEW YORK, Feb. 7 Immediate ... quality medical care and can mean the,difference between ... Health,Record (EHR) systems, used by physicians, offices in ... those critical moments.,McGraw-Hill Higher Education has published a ...
... on Bisphenol,A in Baby Bottles, Food and Beverage Containers, ... state,and national environmental health organizations in the U.S. and ... of bisphenol A (BPA) in baby,bottles and other food ... study that demonstrates the toxic chemical BPA leaches from ...
... WEST CHESTER, Ohio, Feb. 7 AtriCure, Inc.,(Nasdaq: ... in cardiac surgical,ablation products, announced today the appointment of ... Collar recently retired from a,distinguished career with The Procter ... Global Pharmaceuticals and Personal Health,business., "We are pleased ...
Cached Medicine News:Health News:The trouble with hybrids 2Health News:Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation 2Health News:McGraw-Hill Higher Education Publishes Text on Innovative Electronic Health Records System 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 3Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 4Health News:AtriCure Appoints Mark A. Collar to its Board of Directors 2
... The new Amsco 3080/3085 SP Bariatric ... width capacity and expanded surgical capabilities for ... extensions are rated for patients up to ... and easy attachment and full positioning capability. ...
... The new Amsco 3080/3085 SP Bariatric Foot ... capacity and expanded surgical capabilities for Amsco ... The Amsco Foot Extension is rated for ... designed for secure and easy attachment and ...
... The Pulsavac Plus System offers a ... Debridement System. High power efficiently clears bone ... Specific tips are available for hip and ... a wide range of pressure options for ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono...
Medicine Products: